Orchard Therapeutics is a biotechnology company that develops gene therapies for rare diseases. The company's gene therapy approach seeks to transform a patient's own blood stem cells into a gene-modified drug product to treat the patient's disease. Orchard's pipeline includes treatments for primary immune deficiencies, inherited metabolic disorders, and blood disorders. The company was founded in 2015 and is headquartered in London, UK.